An observational study in Lung Cancer, sponsored by Tata Memorial Hospital. Completed at 1 site in India. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-08-07.
Sponsored by Tata Memorial Hospital · Observational
Does the routine clinical practice of follow up after primary treatment in lung cancer patients has any utility.
Patients of cancer, after their primary treatment are subsequently called for follow up visits to assess the disease status. This has two important implications from the point of view of resource management. One, patients often have to travel long distances to report to the hospital and have to take care of other logistics such as their accommodation, local travel and food. Further often the patient travels with 1-2 attendants which adds to the logistic burden. Also, these patients of follow up also contribute to the load on existing hospital services. Many authors have speculated that follow-up visits generate anxiety about possible disease recurrence. On the other hand, many others have suggested that although there may be a transient increase in anxiety, patients are ultimately reassured by this practice. Hence, there is no firm evidence for the practice and the need for follow up in oncology care.
7,243 studies on the registry are indexed under Lung Neoplasms; 1,557 are open to participants now.
This study's enrollment of 200 is close to the median of 189 across 1,514 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Tata Memorial Hospital is the lead sponsor of 97 studies on the registry; 20 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All curative lung cancer patients after there intial primary treatment who have already been given scheduled appointment shall be called telephonically every 3 months. A set of questions shall be asked to the patient in his /her vernacular during the telephonic interview.After the telephonic interview, the patients shall then report to the cancer care specialist at the Hospital for the due follow up visit.
Exclusion Criteria:
Concurrence Between the Telephonic Interview and the Physician Assessment
The Prevalence and bias adjusted Kappa (PABAK) score for concurrence between telephonic and physician assessment of disease status of each patient at each follow up visit was analysed.
Time frame: 2 years
Cost Analysis
On average, each patient spent INR 5117.10 on travel and INR 3079.06 on lodging per follow up visit.
Time frame: 2 years
| Milestone | Total Cohort |
|---|---|
| Started | 200 |
| Completed | 61 |
| Not completed | 139 |
| Withdrew: Death | 136 |
| Withdrew: Lost to follow-up | 3 |
The Prevalence and bias adjusted Kappa (PABAK) score for concurrence between telephonic and physician assessment of disease status of each patient at each follow up visit was analysed.
| probability | Total Cohort |
|---|---|
| Concurrence Between the Telephonic Interview and the Physician Assessment | 0.64 (0.58 to 0.70) |
On average, each patient spent INR 5117.10 on travel and INR 3079.06 on lodging per follow up visit.
| Indian Rupees | Total Cohort |
|---|---|
| Average cost of travel | 5117.10 ± 10370.91 |
| Average cost of lodging | 3079.06 ± 6929.57 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total Cohort | — | 0/200 (0%) | 0/200 (0%) |
| Age, Continuous(years) | Total Cohort |
|---|---|
| Median | 56 (50 to 63) |
| Sex: Female, Male(Participants) | Total Cohort |
|---|---|
| Female | 33 |
| Male | 167 |
| Region of Enrollment(participants) | Total Cohort |
|---|---|
| India | 200 |
| Stage(participants) | Total Cohort |
|---|---|
| Stage I | 20 |
| Stage II | 25 |
| Stage III | 152 |
| Stage IV | 3 |
| Histology(participants) | Total Cohort |
|---|---|
| Adenocarcinoma | 80 |
| Squamous Carcinoma | 67 |
| Other NSCLC | 23 |
| Small Cell Carcinoma | 30 |
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Hospital